CompletedPhase 2

Trimetazidine as an Adjunct to Enhance Clopidogrel Response.

Trinidad and Tobago24 participantsStarted 2018-07-01

Plain-language summary

Hypothesis: Trimetazidine improves Clopidogrel response in patients. • The investigators postulate that the inhibition of platelet aggregation in response to Clopidogrel may be accentuated by Trimetazidine, i.e. Trimetazidine enhances Clopidogrel response. Null Hypothesis: There is no difference in Clopidogrel response in patients with stable coronary artery disease with adjunctive Trimetazidine.

Who can participate

Age range18 Years – 74 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. between 18 and 74 years of age,
✓. have stable coronary artery disease, already on DAPT with aspirin and clopidogrel for at least 6 months,
✓. not on any physician-prescribed medications or complementary/alternative therapies,

Exclusion criteria

✕. presence of active internal bleeding or history of bleeding diathesis or clinical findings associated with an increased risk of bleeding,
✕. history of ischemic or hemorrhagic stroke, transient ischemic attack, intracranial neoplasm, arteriovenous malformation, or aneurysm,
✕. clinical and/or hemodynamic instability,
✕. within 1 month of placement of a bare metal stent,
✕. within 30 days of coronary artery bypass graft surgery or PCI without a stent placed,
✕. planned coronary revascularization,
✕. treatment with fibrin-specific fibrinolytic therapy \<24 h or non-fibrin-specific fibrinolytic therapy \<48 h,
✕. use of an oral anticoagulation agent or international normalized ratio \>1.5,

What they're measuring

Change in Platelet Reactivity Units at baseline compared to post-intervention with Trimetazidine

Timeframe: 10-14 days

Trial details

NCT IDNCT03603249

SponsorThe University of The West Indies

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-04-01

View on ClinicalTrials.gov More Platelet Dysfunction Due to Drugs trials